Wall Street analysts expect CRISPR THERAPTC (NASDAQ:CRSP) to report sales of $2.05 million for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for CRISPR THERAPTC’s earnings, with the lowest sales estimate coming in at $500,000.00 and the highest estimate coming in at $3.60 million. CRISPR THERAPTC reported sales of $1.55 million during the same quarter last year, which indicates a positive year-over-year growth rate of 32.3%. The business is expected to report its next quarterly earnings report on Tuesday, November 28th.

On average, analysts expect that CRISPR THERAPTC will report full year sales of $2.05 million for the current fiscal year, with estimates ranging from $7.30 million to $13.60 million. For the next fiscal year, analysts forecast that the business will report sales of $24.00 million per share. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover CRISPR THERAPTC.

CRISPR THERAPTC (NASDAQ:CRSP) last issued its quarterly earnings results on Thursday, August 10th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.06. The business had revenue of $3.60 million for the quarter, compared to the consensus estimate of $3.29 million. CRISPR THERAPTC had a negative return on equity of 47.46% and a negative net margin of 406.61%. CRISPR THERAPTC’s revenue was up 350.0% on a year-over-year basis.

Several research firms have recently issued reports on CRSP. Cann began coverage on shares of CRISPR THERAPTC in a research report on Monday, July 17th. They set a “market perform” rating for the company. Chardan Capital reaffirmed a “buy” rating on shares of CRISPR THERAPTC in a research report on Monday, August 14th. SunTrust Banks, Inc. began coverage on shares of CRISPR THERAPTC in a research report on Thursday, July 13th. They set a “hold” rating and a $16.00 price objective for the company. Finally, Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of CRISPR THERAPTC in a research report on Tuesday, July 18th. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $21.92.

CRISPR THERAPTC (CRSP) opened at 19.10 on Friday. CRISPR THERAPTC has a 12 month low of $11.63 and a 12 month high of $25.00. The firm’s market capitalization is $775.29 million. The stock’s 50 day moving average price is $18.50 and its 200-day moving average price is $17.81.

WARNING: “Zacks: Analysts Anticipate CRISPR THERAPTC (CRSP) Will Post Quarterly Sales of $2.05 Million” was first published by American Banking News and is the property of of American Banking News. If you are viewing this piece on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2017/09/08/zacks-analysts-anticipate-crispr-theraptc-crsp-will-post-quarterly-sales-of-2-05-million.html.

In related news, CEO Rodger Novak sold 10,825 shares of the business’s stock in a transaction on Thursday, June 22nd. The shares were sold at an average price of $15.37, for a total value of $166,380.25. Following the completion of the sale, the chief executive officer now directly owns 1,225,830 shares of the company’s stock, valued at $18,841,007.10. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Kurt Von Emster sold 88,011 shares of the business’s stock in a transaction on Monday, August 28th. The shares were sold at an average price of $19.79, for a total transaction of $1,741,737.69. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 827,921 shares of company stock valued at $15,063,254. Corporate insiders own 39.98% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the stock. IHT Wealth Management LLC purchased a new stake in CRISPR THERAPTC in the first quarter valued at $110,000. Monashee Investment Management LLC lifted its position in CRISPR THERAPTC by 208.7% in the first quarter. Monashee Investment Management LLC now owns 22,186 shares of the company’s stock valued at $473,000 after acquiring an additional 15,000 shares during the last quarter. Paulson & CO. Inc. purchased a new stake in CRISPR THERAPTC in the first quarter valued at $1,099,000. Credit Suisse AG purchased a new stake in CRISPR THERAPTC in the first quarter valued at $1,742,000. Finally, Wellington Management Group LLP lifted its position in CRISPR THERAPTC by 0.4% in the first quarter. Wellington Management Group LLP now owns 747,450 shares of the company’s stock valued at $16,272,000 after acquiring an additional 3,070 shares during the last quarter. 23.90% of the stock is owned by hedge funds and other institutional investors.

CRISPR THERAPTC Company Profile

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Get a free copy of the Zacks research report on CRISPR THERAPTC (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for CRISPR THERAPTC (NASDAQ:CRSP)

Receive News & Ratings for CRISPR THERAPTC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR THERAPTC and related companies with MarketBeat.com's FREE daily email newsletter.